CFB
NVAX icon

Cullen/Frost Bankers’s Novavax NVAX Stock Holding History

Cullen/Frost Bankers’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5
Closed – – 1169
2022
Q3 		$0 Buy
+5
New +$217 ﹤0.01% 1178

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIG
Herr Investment Group Austin, Texas $1.5B AUM 29.27% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cullen/Frost Bankers's NVAX Position: Q4 2022 in Review

Cullen/Frost Bankers sold out of Novavax (NVAX) in Q4 2022, closing a stake of 5 shares.

Cullen/Frost Bankers first reported a position in NVAX in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 253 funds tracked by Wall St. Rank hold NVAX as of Q4 2022.

  • Cullen/Frost Bankers reported no remaining Novavax position as of Q4 2022 after selling out during the quarter.
  • Cullen/Frost Bankers sold 5 Novavax shares in Q4 2022.
  • Cullen/Frost Bankers first reported a position in Novavax in Q3 2022 and held it in 1 quarter.
  • Cullen/Frost Bankers's Novavax position peaked at $0 in Q3 2022.
  • 253 funds tracked by Wall St. Rank held Novavax as of Q4 2022.

Based on Cullen/Frost Bankers's 13F filing for Q4 2022, filed 13 Feb 2023.